OPRX

OptimizeRx Corporation

7.81 USD

Last updated Sep 5, 11:43 UTC

Yesterday HIGH

$7.89

Yesterday LOW

$7.66

52w HIGH

$22.25

52w LOW

$4.54

EPS

0.16

PE

48.81

Next Earnings

Nov 5, 2026

Overview News Insider Transactions Government Trades Fundamentals

OptimizeRx Corporation stock is up 15.88% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 29 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Wed May 13, 2026

Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7

Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.
Benzinga Newsdesk

Wed May 13, 2026

OptimizeRx shares are trading lower after the company reported Q1 financial results and cut its FY26 sales guidance below estimates.
Benzinga Newsdesk

Wed May 13, 2026

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
Benzinga Insights

Tue May 12, 2026

OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga Insights

Tue May 12, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Newsdesk

Tue May 12, 2026

OptimizeRx shares are trading lower after the company reported Q1 financial results and cut its FY26 sales guidance below estimates.
Benzinga Newsdesk

Tue May 12, 2026

OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est

OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.
Benzinga Newsdesk

Tue May 12, 2026

OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08 per share from the same
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026
Benzinga Newsdesk

Mon May 11, 2026

OptimizeRx Launches New Programmatic Connection Point Between OptimizeRx's Proprietary EHR Network And DSPs

OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important

Citizens

Fri Aug 14, 14:57

buy

confirm

Advanced Data Unlock

Stephen Silvestro, Chief Executive Officer

Thu Aug 20, 2026

OPRX Recent Insider Trades and Stock Chart

79,200 shares awarded
Andrew DSilva, Chief Business Officer

Thu Aug 20, 2026

OPRX Recent Insider Trades and Stock Chart

57,600 shares awarded
Brendan Merrell, CHIEF OPERATING OFFICER

Thu Aug 20, 2026

OPRX Recent Insider Trades and Stock Chart

57,600 shares awarded
Marion K. Odence-Ford, Chief Legal & Admin Officer

Thu Aug 20, 2026

OPRX Recent Insider Trades and Stock Chart

57,600 shares awarded